49 results about "COPD" patented technology

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention discloses an intelligent early warning system for acute exacerbation of COPD home NPPV, which belongs to the technical field of medical treatment and comprises a real-time multi-dimensional physiological data time sequence acquisition module, a COPD acute exacerbation prediction model and an early warning module. The real-time multi-dimensional physiological data time sequence acquisition module is used for acquiring a real-time multi-dimensional physiological data time sequence of a patient; the COPD acute exacerbation prediction model is used for outputting the probability that the patient has COPD acute exacerbation in the future according to the input real-time multi-dimensional physiological data time sequence; and the early warning module is used for performing early warning when the probability of acute exacerbation of COPD of the patient in the future is greater than a preset threshold value. According to the method, the prediction precision of whether COPD acute exacerbation occurs in the future can be improved, and early discovery and early treatment are realized.

The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as potent inhibitors of transforming growth factor-beta receptor I (also known as activin receptor-like kinase 5) (TGFβRI) / ALK5. Other objects of the present invention are to provide processes for preparing these compounds; pharmaceutical compositions comprising an effective amount of these compounds; the use of said compounds for the preparation of a medicament for the treatment of pathological conditions or diseases which can be ameliorated by the inhibition of transforming growth factor-beta receptor I (TGFβRI) / ALK5, such as respiratory diseases, including idiopathic pulmonary fibrosis, asthma, COPD and lung cancer and skin and ocular fibrotic disorders.

The invention relates to the technical field of medical image processing, and discloses a chronic obstructive pulmonary emphysema distribution quantitative method and system based on multi-scale segmentation, and the method comprises the steps: carrying out the anisotropic diffusion filtering noise reduction of a chest CT image; segmenting a lung field and removing a blood vessel bronchial structure by adopting a region growing algorithm; multi-scale image representation is constructed based on a Gaussian pyramid, an emphysema candidate area is identified in a coarse scale layer, and a boundary is accurately drawn by adopting a self-adaptive threshold value in a fine scale layer; extracting local texture features to distinguish the lobular central emphysema and the total lobular emphysema; dividing severity levels according to spatial aggregation characteristics and density gradient distribution, and calculating an air swelling volume ratio and a distribution heterogeneity index; the three-dimensional pseudo-color volume is used for drawing visualization, a structured quantitative report is generated, accurate segmentation and subtype classification of the emphysema area are achieved, and comprehensive quantitative analysis indexes are provided.

This invention relates to catheter and handle assemblies for tissue treatment. More specifically, the invention relates to a catheter assembly having an elongated shaft, an ablation component coupled to one end of the shaft, and a handle coupled to the other end of the shaft. The handle facilitates axial and circumferential positioning of the ablation component via the shaft in an airway, tubing, or blood vessel for tissue treatment. Embodiments include using the handle during treatment of lung diseases such as COPD and asthma to facilitate axial and circumferential positioning of the shaft and ablation component through and independently of the working channel of a bronchoscope.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of invertible pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape. In these embodiments, a portion of the device is invertible. Thus, each device is able to store energy at least in the inversion, wherein the energy is utilized to continually tension the lung as the device relaxes toward its original shape.

The present disclosure describes a sulfate salt form of vapendavir and a pharmaceutical composition containing the same. Methods of treating a subject having a respiratory enterovirus by administering to the subject a pharmaceutical composition including a therapeutically effective amount of the vapendavir sulfate are also described, wherein the subject may or may not also have COPD or asthma.

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).

A method to assess the disease status, determine the mean / average control of the disease and monitor the compliance to treatment over a period of time of a respiratory disease, comprising of predicting the degree of airway inflammation and disease activity by measuring the inflammatory markers, evaluating the mucosal integrity / damage by measuring the moisture levels of the exhaled air, evaluating the breathing function and obstruction by measuring the FEV1 value, and evaluating the symptom control by determining the COPD Score.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The present invention relates a process for preparing a compound of Formula XX wherein: R1 is hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is an N-containign heterocyclyl or heteroaryl; and Q is optionally substitued aryl or heteroaryl. Furthermore a compound of the present invention are useful in the treamtment of various inflammatory, autoimmune and allergic diseases, such as method of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoartluitis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the overexpression and over-activation of a matrix metalloproteinase using the compound.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of invertible pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape. In these embodiments, a portion of the device is invertible. Thus, each device is able to store energy at least in the inversion, wherein the energy is utilized to continually tension the lung as the device relaxes toward its original shape.

The present disclosure describes a sulfate salt form of vapendavir and a pharmaceutical composition containing the same. Methods of treating a subject having a respiratory enterovirus by administering to the subject a pharmaceutical composition including a therapeutically effective amount of the vapendavir sulfate are also described, wherein the subject may or may not also have COPD or asthma.

The invention relates to a catheter and handle assembly for treating tissue. More specifically, the present invention relates to catheter assemblies having an elongate shaft, an ablation assembly coupled to one end of the shaft, and a handle coupled to the other end of the shaft. The handle facilitates axial and circumferential positioning of the ablation assembly through the shaft in the airway, conduit or vessel for treatment of tissue. Embodiments include the use of a handle to facilitate axial and circumferential positioning of the shaft and ablation assembly through and independent of the working channel of the bronchoscope during the treatment of pulmonary diseases such as COPD and asthma.

The present application relates to the field of medical imaging technology, specifically to a COPD early warning method and system based on chest CT parameters, comprising the following steps: based on chest CT image data, extracting pixel data of lung lobe anatomical region, segmenting airway tree structure, identifying bronchial wall boundary, screening gradient change points, and generating airway wall boundary point set. In the present application, by refining the lung lobe anatomical region, segmenting the airway tree structure, accurately positioning the bronchial wall boundary, calculating the airway wall thickness, correcting abnormal fluctuations, improving the stability of the thickness parameter, using the thickness parameter to calculate the airflow passage cross-sectional area, analyzing the lung lobe ventilation volume and ventilation change, quantifying the lung ventilation imbalance degree, screening the ventilation restricted area, analyzing the relationship between the wall thickness and the ventilation change rate, extracting the abnormal growth area, marking the ventilation restriction severity, setting the early warning threshold, calculating the abnormal index mean value, marking the risk area, enhancing the ventilation abnormality recognition hierarchy, and improving the early warning ability of COPD.

Described herein are methods of treating cystic fibrosis, asthma, COPD, and other airway related diseases in a patient by administering a therapeutically effective amount of a specific enantiomer, R-vanzacaftor or a pharmaceutically acceptable salt thereof, to the patient.

The present disclosure relates to a COPD ventilator dependence risk prediction method and device, an intelligent decision-making method and system, the method comprising: constructing a quantitative index system of a respiratory supply and demand balance model; obtaining multi-modal data of a patient, calculating features of the multi-modal data according to the quantitative index system to obtain a supply-side feature vector, a demand-side feature vector and a load-side feature vector; processing the feature vectors using a trained deep learning model to obtain a ventilator dependence risk prediction result; obtaining the ventilator dependence risk prediction result and a respiratory homeostasis index of the patient; performing cluster analysis on the feature vectors to identify a ventilator dependence phenotype and calculate a subtype probability distribution; and determining an individualized treatment intervention strategy according to the ventilator dependence risk prediction result, the respiratory homeostasis index and the ventilator dependence phenotype. The present disclosure can realize accurate assessment of ICU ventilator dependence risk and intelligent generation of intervention strategies.

The invention provides a chronic disease health-care system for institutional old-age care, and relates to the field of intelligent medical treatment. The system comprises a periodic physical examination module for performing periodic physical examination on a crowd to obtain a physical examination result; the grading and bidding module is used for dividing the crowd into low-risk, medium-risk and high-risk groups according to the physical examination result; the low-risk group, the medium-risk group and the high-risk group are managed by units of different levels; the high-risk group management module at least comprises a chronic disease special case unit and is mainly used for creating a chronic disease file for a patient and performing chronic disease management service on the patient; the chronic disease type comprises any one or more of hypertension, diabetes, cerebral apoplexy, coronary heart disease, chronic obstructive pulmonary disease and fundus disease. According to the invention, a patient-centered'Internet + chronic disease management 'mode is adopted, chronic diseases are classified, graded and bid-divided, a county hospital-community / town health center-health station integrated system network is formed, early discovery of chronic diseases is truly realized, the morbidity of high-risk groups is reduced, and the disability and fatality rates are reduced.

The present invention relates to compounds of general formula (I) that inhibit the JAK family of non-receptor tyrosine kinases (JAK1, JAK2, JAK3, and TYK2); methods for preparing such compounds; pharmaceutical compositions containing them; and their therapeutic use. The compounds of the invention may be useful in the treatment of diseases or conditions associated with dysregulation of non-receptor kinases of the JAK family; in particular, for the treatment of various inflammatory diseases, such as asthma, COPD, and other respiratory diseases.

This invention discloses a COPD identification system based on the audio representation of respiratory signals from a surface radar, comprising: a signal acquisition module for acquiring echo data of the target object based on surface radar and performing a range-dimensional fast Fourier transform to extract the phase sequence of a stable target to obtain respiratory micro-motion signals; a respiratory audio generation module for encoding and normalizing the respiratory micro-motion signals to obtain respiratory representation audio; a COPD pathological phase sensing module for overlapping segmentation of the respiratory representation audio and generating a Mel time-frequency sequence based on COPD pathological feature frequency bands; and a deep learning classification module for using the Mel time-frequency sequence as input data, learning pathological patterns in the time-frequency features using a global attention mechanism, and outputting COPD prediction results. This invention utilizes millimeter-wave radar and the collaborative work of a series of modules to achieve completely imperceptible respiratory monitoring, making it particularly suitable for the early identification and diagnosis of COPD.

Described herein are devices, systems and methods for monitoring the use of a nebulized medication, such as can be administered using a nebulizer. These can be used for monitoring a patient undergoing treatment for COPD and improve compliance to the recommended therapy. Monitored parameters include flow, humidity and acceleration and provide data as to the quantity and quality of nebulizer use.

The invention provides certain imidazotriazine compounds of formula I as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I or II to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to a TCM composition, preparation, preparation method, and application for use in the peri-discharge period of acute exacerbations of COPD. The TCM composition comprises the following raw materials: 10-20 parts of *Codonopsis pilosula*, 10-25 parts of *Adenophora stricta*, 15-30 parts of *Clam shell*, 8-15 parts of *Fritillaria thunbergii*, 8-12 parts of *Platycodon grandiflorus*, 8-15 parts of *Paeonia lactiflora*, 8-12 parts of *Aster tataricus*, 8-12 parts of *Lepidium apetalum*, and 8-12 parts of *Pheretima aspergillum*. The TCM preparation derived therefrom can be in the following dosage forms: decoction, paste, tablets, capsules, granules, pills, powders, drop pills, mixtures, or oral liquids. It can be used to prepare drugs that relieve cough, sputum, and shortness of breath, and is suitable for the peri-discharge period of acute exacerbations of COPD.

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).

The present invention relates to methods of treating chronic obstructive pulmonary disesse (COPD) in an enhanced patient population, particularly by administering an anti- IL5 antibody or fragment thereof.

The invention discloses a construction method of a lung organ model based on a COPD patient source, relates to the technical field of biomedical model construction, and efficiently constructs a lung organ model retaining COPD pathological characteristics by optimizing tissue treatment, cell separation and three-dimensional culture conditions. The method comprises the following specific steps: acquiring fresh surgical resected lung tissues of a COPD patient; primary lung epithelial cells are obtained by combining collagenase IV digestion with cell filtration and lung interstitial cell separation; the method comprises the following steps: culturing cells by a matrigel embedding method, and culturing for 10 days by utilizing an amplification culture medium to form an organ-like structure; and then switching to a differential culture medium and inducing for 7 days to realize functional differentiation of the airway epithelial cells and the pulmonary alveolar cells. According to the method, the construction efficiency and stability of the organoid are remarkably improved, the constructed model can simulate the COPD pathological microenvironment, and the method is suitable for disease mechanism research, drug screening and individualized treatment evaluation and has high reproducibility and clinical transformation potential.

An IL33 antagonist, alone or in combination with an IL-4R antagonist, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyp in a subject having one or more risk alleles in the intron IL1RL1 variant rs1420101, in the IL33 variant rs1342326, both, or in variants of their linkage imbalance.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof. 20 24 22 02 14 30 S ep 2 02 4 A B S T R A C T 2 0 2 4 2 2 0 2 1 4 3 0 2 0 2 4 S e p